Clinical trials: Chidamide
Peripheral Blood Stem Cell Transplantation
Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma Underwenting Haploidenticl…
- Trial name
- NCT05075681
- Testing
- Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
Peripheral T-cell Lymphoma
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
This is a single-arm, single-center Phase II clinical trial for patients with relapsed or refractory Peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT04052659
- Testing
- Sintilimab, Chidamide, Azacidine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
Neuroendocrine Tumors, Neuroendocrine Carcinoma
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
The purpose of this study is to explore the efficacy and safety of chidamide combined with etoposide and cisplatin/carboplatin in the first-line treatment of advanced extrapulmonary neuroendocrine carcinoma.
- Trial name
- NCT05076786
- Testing
- Chidamide, Etoposide + Cisplatin/Carboplatin
- Where
- 3 sites in China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital
Lymphoma, Large B-Cell, Diffuse
Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide with R-GemOx(rituximab、gemcitabine plus oxaliplatin) regimen in the treatment of transplant-ineligible…
- Trial name
- NCT04022005
- Testing
- Chidamide, Rituximab, Gemcitabine,Oxaliplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
BTK Inhibitors, Histone Deacetylase Inhibitor
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
Zanubrutinib, as a new generation of BTK inhibitors, has shown more potent antitumor activity and lower adverse reactions than ibrutinib in head-to-head clinical studies, which make it a promising regimen for B cell lymphoma.
- Conditions
- BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell Lymphoma
- Trial name
- NCT06890585
- Testing
- ZCR-CHOP, R-CHOP
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Li Zhiming
Follicular Lymphoma, Refractory B-Cell Lymphoma
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
- Conditions
- Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06158386
- Testing
- Chidamide combined with Linperlisib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Acute Myeloid Leukemia
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.
- Trial name
- NCT06220162
- Testing
- chidamide in combination with venetoclax and azacitidine (VAC)
- Where
- China
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Colorectal Cancer Metastatic
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
The prognosis of most patients with unresectable locally advanced or metastatic colorectal cancer (CRC) remains poor despite the advancements in chemotherapy and target therapy.
- Trial name
- NCT06685276
- Testing
- Fruquintinib, Sintilimab, Chidamide
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Dai, Guanghai
HIV (Human Immunodeficiency Virus)
A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV
HIV viral reservoirs represent the major barrier to curing AIDS, and effectively reducing viral reservoirs in people living with HIV through different strategies has become a research priority in the HIV field.
- Trial name
- NCT07635992
- Testing
- Ibalizumab Combined with Chidamide
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Peripheral T-cell Lymphoma
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
To evaluate the efficacy and safety of bendamustine combined with chidamide and lenalidomide in R/R PTCL patients.
- Trial name
- NCT07072221
- Testing
- BCL regimen, Cohort 1 (ASCT-eligible), Cohort 2 (ASCT--ineligible)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Peripheral T-cell Lymphoma
Linperlisib Combined With Chidamide in Patients With PTCL
The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06421948
- Testing
- Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Yanyan Liu
Hormone Receptor-positive Advanced Breast Cancer
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
This trial is a single-arm study. The purpose of the trial is to evaluate the efficacy and safety of chidamide and fulvestrant in HR+/HER2- breast cancer that has failed prior adjuvant endocrine therapy with CDK4/6 inhibitors.
- Trial name
- NCT05806047
- Testing
- chidamide combined with fulvestrant
- Volunteers
- 23 people
- Sponsor
- Fudan University
Breast Cancer
Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Triple-negative breast cancer has always been a difficult problem in clinical practice because of its young onset age, high aggressiveness, no clear therapeutic target and poor clinical prognosis.
- Trial name
- NCT05749575
- Testing
- Chidamide Plus Toripalimab Plus Paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
DLBCL
CR-CHOP+X in Previously Untreated DEL
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL…
- Trial name
- NCT06701357
- Testing
- CR-CHOP+PD1 inhibitor, CR-CHOP + Orelabrutinib, CR-CHOP + decitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Ruijin Hospital
Peripheral T Cell Lymphoma
Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma
This trial intends: 1.To evaluate the concentration of Chidamide in the serum and cerebral-spinal fluid of PTCL patients at certain time points after taking the medicine, to evaluate the pharmacokinetics of Chidamide in these…
- Trial name
- NCT02944812
- Testing
- Chidamide
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Guangdong Provincial People's Hospital
Leukemia, Acute, MDS
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.
- Trial name
- NCT03336632
- Testing
- Chidamide, Cyclophosphamide, cyclosporine A
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Sichuan University
Relapsed or Refractory DLBCL
Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)
To assess the efficacy and safety of Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in the Treatment of Relapsed or Refractory DLBCL
- Trial name
- PCR (NCT05115409)
- Testing
- Anti-PD-1 Antibody Plus Chidamide and Rituximab
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
NK/T Cell Lymphoma
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
To observe the safety, tolerability and clinical effects of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma.
- Trial name
- NCT04038411
- Testing
- PD-1 Antibody, chidamide, lenalidomide and etoposide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Mingzhi Zhang
Chidamide, Hemophagocytic Lymphohistiocytosis
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
Chidamide combines with VP-16 and methylprednisolone in HLH
- Trial name
- NCT05137522
- Testing
- Chidamide combines with VP-16 and methylprednisolone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Breast Cancer
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.
- Trial name
- NCT06547476
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
- Volunteers
- 40 people
- Sponsor
- Guangdong Provincial People's Hospital